Tardive dyskinesia

CNS Spectrums

Volumn 12, Issue 10, 2007, Pages 747-750

  Lieberman, Jeffrey A ^a,b,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Clinical Antipsychotic Trials of Intervention Effectiveness Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BIFEPRUNOX; PALIPERIDONE; NEUROLEPTIC AGENT;

CHOREOATHETOSIS; CLINICAL FEATURE; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MOTOR DYSFUNCTION; NOTE; POSTMENOPAUSE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TARDIVE DYSKINESIA; TIC; TREATMENT WITHDRAWAL; ARTICLE; DIFFERENTIAL DIAGNOSIS; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; HISTORY; HOSPITALIZATION; INTERVIEW; PATHOPHYSIOLOGY; PSYCHIATRY; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DIAGNOSIS, DIFFERENTIAL; DYSKINESIA, DRUG-INDUCED; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PSYCHIATRY; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 35948955191     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285290001542X     Document Type: Note

References (8)

1. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry. 2000;61(suppl 4):21-26.
2. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65(suppl 9):21-24.
3. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry. 2004;65(suppl 9):16-20.
4. Adler LA. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56:836-841.
5. Lieberman JA, Stroup S, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. N Engl J Med. 2005;353:1209-1223.
6. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087.
7. Gaebel W, Reisbeck M, Wölwer W, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on schizophrenia. J Clin Psychiatry. In press.
8. Fleischhacker WW, Kahn R. Paper presented at: Winter Workshop of the American College of Neuropsychopharmacology. February 2-8, 2006; Davos, Switzerland.